Matthias W Beckmann
Return of individual genomic research results within the PRAEGNANT multicenter registry study.
Huebner H, Ruebner M, Kurbacher C, Hadji P, Hartkopf A, Lux M, Huober J, Uhrig S, Taran F, Overkamp F, Tesch H, Häberle L, Luftner D, Wallwiener M, Müller V, Beckmann M, Hein A, Belleville E, Untch M, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Ettl J, Fasching P, Michel L. Return of individual genomic research results within the PRAEGNANT multicenter registry study. Breast Cancer Res Treat 2022
21.11.2022Return of individual genomic research results within the PRAEGNANT multicenter registry study.
21.11.2022Breast Cancer Res Treat 2022
Huebner Hanna, Ruebner Matthias, Kurbacher Christian, Hadji Peyman, Hartkopf Andreas D, Lux Michael P, Huober Jens, Uhrig Sabrina, Taran Florin-Andrei, Overkamp Friedrich, Tesch Hans, Häberle Lothar, Luftner Diana, Wallwiener Markus, Müller Volkmar, Beckmann Matthias W, Hein Alexander, Belleville Erik, Untch Michael, Janni Wolfgang, Fehm Tanja N, Kolberg Hans-Christian, Wallwiener Diethelm, Brucker Sara Y, Schneeweiss Andreas, Ettl Johannes, Fasching Peter A, Michel Laura L
MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
Huebner H, Tesch H, Brucker S, Blohmer J, Fehm T, Heinrich G, Rezai M, Beckmann M, Fasching P, Janni W, Schneeweiss A, Nabieva N, Jückstock J, Häberle L, Müller V, Schrader I, Lorenz R, Forstbauer H, Fink V, Schochter F, Bekes I, Mahner S, Rack B. MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. Cancers (Basel) 2022; 14
28.03.2022MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
28.03.2022Cancers (Basel) 2022; 14
Huebner Hanna, Tesch Hans, Brucker Sara Y, Blohmer Jens-Uwe, Fehm Tanja N, Heinrich Georg, Rezai Mahdi, Beckmann Matthias W, Fasching Peter A, Janni Wolfgang, Schneeweiss Andreas, Nabieva Naiba, Jückstock Julia, Häberle Lothar, Müller Volkmar, Schrader Iris, Lorenz Ralf, Forstbauer Helmut, Fink Visnja, Schochter Fabienne, Bekes Inga, Mahner Sven, Rack Brigitte
Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial
Friedl T, Tesch H, Mahner S, Brucker S, Heinrich G, Häberle L, Fasching P, Beckmann M, Coleman R, Janni W, Schneeweiss A, Jückstock J, Fehm T, Müller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, Fink V, Bekes I, Huober J, Rack B. Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. JAMA Oncol 2021; 7:1149-1157.
01.08.2021Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial
01.08.2021JAMA Oncol 2021; 7:1149-1157
Friedl Thomas W P, Tesch Hans, Mahner Sven, Brucker Sara Y, Heinrich Georg, Häberle Lothar, Fasching Peter A, Beckmann Matthias W, Coleman Robert E, Janni Wolfgang, Schneeweiss Andreas, Jückstock Julia, Fehm Tanja, Müller Volkmar, Lichtenegger Werner, Blohmer Jens, Lorenz Ralf, Forstbauer Helmut, Fink Visnja, Bekes Inga, Huober Jens, Rack Brigitte
Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"
Schneeweiss A, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Klein E, Kurbacher C, Ettl J, Luftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Brucker S. Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany". Breast 2021; 55:138-139.
05.01.2021Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany"
05.01.2021Breast 2021; 55:138-139
Schneeweiss Andreas, Lux Michael P, Müller Volkmar, Nabieva Naiba, Overkamp Friedrich, Tesch Hans, Laakmann Elena, Taran Florin-Andrei, Seitz Julia, Thomssen Christoph, Untch Michael, Wimberger Pauline, Wuerstlein Rachel, Volz Bernhard, Wallwiener Diethelm, Wallwiener Markus, Klein Evelyn, Kurbacher Christian M, Ettl Johannes, Luftner Diana, Beckmann Matthias W, Belleville Erik, Fasching Peter A, Fehm Tanja N, Geberth Matthias, Häberle Lothar, Hadji Peyman, Hartkopf Andreas D, Hielscher Carsten, Huober Jens, Ruckhäberle Eugen, Janni Wolfgang, Kolberg Hans Christian, Brucker Sara Y
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
Huebner H, Beckmann M, Belleville E, Ruebner M, Untch M, Fasching P, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Müller V, Wallwiener M, Kurbacher C, Kuesters G, Hartkopf A, Lux M, Huober J, Volz B, Taran F, Overkamp F, Tesch H, Häberle L, Luftner D, Ettl J. Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. BMC cancer 2020; 20:1091.
11.11.2020Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
11.11.2020BMC cancer 2020; 20:1091
Huebner Hanna, Beckmann Matthias W, Belleville Erik, Ruebner Matthias, Untch Michael, Fasching Peter A, Janni Wolfgang, Fehm Tanja N, Kolberg Hans-Christian, Wallwiener Diethelm, Brucker Sara Y, Schneeweiss Andreas, Müller Volkmar, Wallwiener Markus, Kurbacher Christian M, Kuesters Geoffrey, Hartkopf Andreas D, Lux Michael P, Huober Jens, Volz Bernhard, Taran Florin-Andrei, Overkamp Friedrich, Tesch Hans, Häberle Lothar, Luftner Diana, Ettl Johannes
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial
De Gregorio A, Schneeweiss A, Tesch H, Mahner S, Brucker S, Blohmer J, Fehm T, Heinrich G, Lato K, Beckmann M, Rack B, Andergassen U, Bekes I, Fink V, Häberle L, Fasching P, Müller V, Schrader I, Lorenz R, Forstbauer H, Friedl T, Bauer E, De Gregorio N, Deniz M, Janni W. Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial. Breast Cancer Res 2020; 22:111.
23.10.2020Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial
23.10.2020Breast Cancer Res 2020; 22:111
De Gregorio Amelie, Schneeweiss Andreas, Tesch Hans, Mahner Sven, Brucker Sara Y, Blohmer Jens-Uwe, Fehm Tanja N, Heinrich Georg, Lato Krisztian, Beckmann Matthias W, Rack Brigitte, Andergassen Ulrich, Bekes Inga, Fink Visnja, Häberle Lothar, Fasching Peter A, Müller Volkmar, Schrader Iris, Lorenz Ralf, Forstbauer Helmut, Friedl Thomas W P, Bauer Emanuel, De Gregorio Nikolaus, Deniz Miriam, Janni Wolfgang
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Michel L, Hielscher C, Mundhenke C, Kurbacher C, Wuerstlein R, Untch M, Overkamp F, Huober J, Janni W, Taran F, Lux M, Wallwiener D, Brucker S, Schneeweiss A, Wimberger P, Huebner H, Hartkopf A, Fasching P, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Volz B, Fehm T. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. Cancers (Basel) 2020; 12
17.10.2020Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
17.10.2020Cancers (Basel) 2020; 12
Michel Laura L, Hielscher Carsten, Mundhenke Christoph, Kurbacher Christian, Wuerstlein Rachel, Untch Michael, Overkamp Friedrich, Huober Jens, Janni Wolfgang, Taran Florin-Andrei, Lux Michael P, Wallwiener Diethelm, Brucker Sara Y, Schneeweiss Andreas, Wimberger Pauline, Huebner Hanna, Hartkopf Andreas D, Fasching Peter A, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Häberle Lothar, Ettl Johannes, Luftner Diana, Wallwiener Markus, Müller Volkmar, Beckmann Matthias W, Belleville Erik, Volz Bernhard, Fehm Tanja N
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
Schneeweiss A, Lux M, Müller V, Nabieva N, Overkamp F, Tesch H, Laakmann E, Taran F, Seitz J, Thomssen C, Untch M, Wimberger P, Wuerstlein R, Volz B, Wallwiener D, Wallwiener M, Klein E, Kurbacher C, Ettl J, Luftner D, Beckmann M, Belleville E, Fasching P, Fehm T, Geberth M, Häberle L, Hadji P, Hartkopf A, Hielscher C, Huober J, Ruckhäberle E, Janni W, Kolberg H, Brucker S. Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. Breast 2020; 54:88-95.
29.08.2020Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
29.08.2020Breast 2020; 54:88-95
Schneeweiss Andreas, Lux Michael P, Müller Volkmar, Nabieva Naiba, Overkamp Friedrich, Tesch Hans, Laakmann Elena, Taran Florin-Andrei, Seitz Julia, Thomssen Christoph, Untch Michael, Wimberger Pauline, Wuerstlein Rachel, Volz Bernhard, Wallwiener Diethelm, Wallwiener Markus, Klein Evelyn, Kurbacher Christian M, Ettl Johannes, Luftner Diana, Beckmann Matthias W, Belleville Erik, Fasching Peter A, Fehm Tanja N, Geberth Matthias, Häberle Lothar, Hadji Peyman, Hartkopf Andreas D, Hielscher Carsten, Huober Jens, Ruckhäberle Eugen, Janni Wolfgang, Kolberg Hans Christian, Brucker Sara Y
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
Lux M, Wimberger P, Hielscher C, Geberth M, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Schneeweiss A, Belleville E, Beckmann M, Müller V, Nabieva N, Hartkopf A, Huober J, Volz B, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Luftner D, Wallwiener M, Brucker S. Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. Cancers (Basel) 2018; 11
21.12.2018Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
21.12.2018Cancers (Basel) 2018; 11
Lux Michael P, Wimberger Pauline, Hielscher Carsten, Geberth Matthias, Abenhardt Wolfgang, Kurbacher Christian, Wuerstlein Rachel, Thomssen Christoph, Untch Michael, Fasching Peter A, Janni Wolfgang, Fehm Tanja N, Wallwiener Diethelm, Schneeweiss Andreas, Belleville Erik, Beckmann Matthias W, Müller Volkmar, Nabieva Naiba, Hartkopf Andreas D, Huober Jens, Volz Bernhard, Taran Florin-Andrei, Overkamp Friedrich, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Häberle Lothar, Ettl Johannes, Luftner Diana, Wallwiener Markus, Brucker Sara Y
Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study
Deniz M, Andergassen U, Steidl J, Trapp E, Fasching P, Häberle L, Beckmann M, Schneeweiss A, Schrader I, Janni W, Rack B, Jueckstock J, Kost B, deGregorio A, DeGregorio N, Bekes I, Widschwendter P, Schochter F, Ernst K, Scholz C, Bauer E, Aivazova-Fuchs V, Weissenbacher T, Friedl T. Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. Breast 2018; 44:81-89.
20.12.2018Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study
20.12.2018Breast 2018; 44:81-89
Deniz Miriam, Andergassen Ullrich, Steidl Julia, Trapp Elisabeth, Fasching Peter A, Häberle Lothar, Beckmann Matthias W, Schneeweiss Andreas, Schrader Iris, Janni Wolfgang, Rack Brigitte, Jueckstock Julia, Kost Bernd, deGregorio Amelie, DeGregorio Nikolaus, Bekes Inga, Widschwendter Peter, Schochter Fabienne, Ernst Kristina, Scholz Christoph, Bauer Emanuel Ca, Aivazova-Fuchs Viktoria, Weissenbacher Tobias, Friedl Thomas Wp
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer
Bjelic-Radisic V, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann M, Blohmer J, Fasching P, Sinn H, Hirsmüller S, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Lux M, Harbeck N, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Buck A, Nöthlings U, Müller V, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück H, von Minckwitz G, Möbus V, Stangl S, Paradies K, Wöckel A, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Kreienberg R, Kopp I, Festl J, Stüber T, Brust K, Krockenberger M, Heuschmann P, Jírů-Hillmann S, Albert U, Budach W, Follmann M, Janni W, Steckelberg A, Feyer P, Petersen C, Bartsch H, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Siedentopf F, Lebeau A, König K, Hahne A, Baumgartner T, Kreipe H, Knoefel W, Denkinger M, Brucker S, Luftner D, Kubisch C, Gerlach C, Honegger C. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer. Geburtshilfe Frauenheilkd 2018; 78:1056-1088.
26.11.2018Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer
26.11.2018Geburtshilfe Frauenheilkd 2018; 78:1056-1088
Bjelic-Radisic Vesna, Dunst Jürgen, Münstedt Karsten, Bick Ulrich, Fallenberg Eva, Tholen Reina, Hung Roswita, Baumann Freerk, Beckmann Matthias W, Blohmer Jens, Fasching Peter, Sinn Hans-Peter, Hirsmüller Susanne, Degenhardt Friedrich, Wenz Frederik, Rick Oliver, Hölzel Dieter, Zaiss Matthias, Kemper Gudrun, Budach Volker, Denkert Carsten, Gerber Bernd, Tesch Hans, Lux Michael P, Harbeck Nadia, Schmidt Marcus, Schmutzler Rita, Schneeweiss Andreas, Schütz Florian, Stickeler Elmar, Thomssen Christoph, Untch Michael, Wesselmann Simone, Bücker Arno, Buck Andreas, Nöthlings Ute, Müller Volkmar, Hadji Peyman, Hauner Hans, Heywang-Köbrunner Sylvia, Huober Jens, Hübner Jutta, Jackisch Christian, Loibl Sibylle, Lück Hans-Jürgen, von Minckwitz Gunter, Möbus Volker, Stangl Stephanie, Paradies Kerstin, Wöckel Achim, Kühn Thorsten, Langer Thomas, Nothacker Monika, Scharl Anton, Schreer Ingrid, Link Hartmut, Engel Jutta, Fehm Tanja, Weis Joachim, Welt Anja, Kreienberg Rolf, Kopp Ina, Festl Jasmin, Stüber Tanja, Brust Katharina, Krockenberger Mathias, Heuschmann Peter U, Jírů-Hillmann Steffi, Albert Ute-Susann, Budach Wilfried, Follmann Markus, Janni Wolfgang, Steckelberg Anke, Feyer Petra, Petersen Cordula, Bartsch Hans Helge, Schulz-Wendtland Rüdiger, Hahn Markus, Hanf Volker, Müller-Schimpfle Markus, Henscher Ulla, Roncarati Renza, Katalinic Alexander, Heitmann Christoph, Siedentopf Friederike, Lebeau Annette, König Klaus, Hahne Andrea, Baumgartner Traudl, Kreipe Hans H, Knoefel Wolfram Trudo, Denkinger Michael, Brucker Sara, Luftner Diana, Kubisch Christian, Gerlach Christina, Honegger Christoph
Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer
Bjelic-Radisic V, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann M, Blohmer J, Sinn H, Hirsmüller S, Tesch H, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Fasching P, Lux M, Harbeck N, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Nöthlings U, Müller V, Möbus V, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück H, von Minckwitz G, Krockenberger M, Wöckel A, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Kühn T, Kreienberg R, Kopp I, Festl J, Stüber T, Brust K, Stangl S, Heuschmann P, Albert U, Budach W, Follmann M, Janni W, Steckelberg A, Feyer P, König K, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Bartsch H, Petersen C, Siedentopf F, Hahne A, Kreipe H, Knoefel W, Denkinger M, Brucker S, Luftner D, Kubisch C, Gerlach C, Lebeau A, Paradies K. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer. Geburtshilfe Frauenheilkd 2018; 78:927-948.
19.10.2018Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer
19.10.2018Geburtshilfe Frauenheilkd 2018; 78:927-948
Bjelic-Radisic Vesna, Dunst Jürgen, Münstedt Karsten, Bick Ulrich, Fallenberg Eva, Tholen Reina, Hung Roswita, Baumann Freerk, Beckmann Matthias W, Blohmer Jens, Sinn Hans-Peter, Hirsmüller Susanne, Tesch Hans, Degenhardt Friedrich, Wenz Frederik, Rick Oliver, Hölzel Dieter, Zaiss Matthias, Kemper Gudrun, Budach Volker, Denkert Carsten, Gerber Bernd, Fasching Peter A, Lux Michael P, Harbeck Nadia, Schmidt Marcus, Schmutzler Rita, Schneeweiss Andreas, Schütz Florian, Stickeler Elmar, Thomssen Christoph, Untch Michael, Wesselmann Simone, Bücker Arno, Nöthlings Ute, Müller Volkmar, Möbus Volker, Hadji Peyman, Hauner Hans, Heywang-Köbrunner Sylvia, Huober Jens, Hübner Jutta, Jackisch Christian, Loibl Sibylle, Lück Hans-Jürgen, von Minckwitz Gunter, Krockenberger Mathias, Wöckel Achim, Langer Thomas, Nothacker Monika, Scharl Anton, Schreer Ingrid, Link Hartmut, Engel Jutta, Fehm Tanja, Weis Joachim, Welt Anja, Kühn Thorsten, Kreienberg Rolf, Kopp Ina, Festl Jasmin, Stüber Tanja, Brust Katharina, Stangl Stephanie, Heuschmann Peter U, Albert Ute-Susann, Budach Wilfried, Follmann Markus, Janni Wolfgang, Steckelberg Anke, Feyer Petra, König Klaus, Schulz-Wendtland Rüdiger, Hahn Markus, Hanf Volker, Müller-Schimpfle Markus, Henscher Ulla, Roncarati Renza, Katalinic Alexander, Heitmann Christoph, Honegger Christoph, Bartsch Hans Helge, Petersen Cordula, Siedentopf Friederike, Hahne Andrea, Kreipe Hans H, Knoefel Wolfram Trudo, Denkinger Michael, Brucker Sara, Luftner Diana, Kubisch Christian, Gerlach Christina, Lebeau Annette, Paradies Kerstin
Update Breast Cancer 2017 - Implementation of Novel Therapies
Lux M, Wallwiener M, Müller V, Beckmann M, Belleville E, Fehm T, Wallwiener D, Brucker S, Schneeweiss A, Luftner D, Huober J, Ettl J, Janni W, Hartkopf A, Nabieva N, Taran F, Overkamp F, Kolberg H, Hadji P, Tesch H, Fasching P. Update Breast Cancer 2017 - Implementation of Novel Therapies. Geburtshilfe Frauenheilkd 2017; 77:1281-1290.
18.12.2017Update Breast Cancer 2017 - Implementation of Novel Therapies
18.12.2017Geburtshilfe Frauenheilkd 2017; 77:1281-1290
Lux Michael P, Wallwiener Markus, Müller Volkmar, Beckmann Matthias W, Belleville Erik, Fehm Tanja N, Wallwiener Diethelm, Brucker Sara Y, Schneeweiss Andreas, Luftner Diana, Huober Jens, Ettl Johannes, Janni Wolfgang, Hartkopf Andreas D, Nabieva Naiba, Taran Florin-Andrei, Overkamp Friedrich, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Fasching Peter A
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry
Hartkopf A, Wimberger P, Hielscher C, Geberth M, Fersis N, Abenhardt W, Kurbacher C, Wuerstlein R, Thomssen C, Untch M, Fasching P, Janni W, Fehm T, Wallwiener D, Brucker S, Belleville E, Beckmann M, Müller V, Huober J, Volz B, Nabieva N, Taran F, Schwitulla J, Overkamp F, Kolberg H, Hadji P, Tesch H, Häberle L, Ettl J, Lux M, Luftner D, Wallwiener M, Schneeweiss A. Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry. Breast 2017; 37:42-51.
26.10.2017Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry
26.10.2017Breast 2017; 37:42-51
Hartkopf Andreas D, Wimberger Pauline, Hielscher Carsten, Geberth Matthias, Fersis Nikos, Abenhardt Wolfgang, Kurbacher Christian, Wuerstlein Rachel, Thomssen Christoph, Untch Michael, Fasching Peter A, Janni Wolfgang, Fehm Tanja N, Wallwiener Diethelm, Brucker Sara Y, Belleville Erik, Beckmann Matthias W, Müller Volkmar, Huober Jens, Volz Bernhard, Nabieva Naiba, Taran Florin-Andrei, Schwitulla Judith, Overkamp Friedrich, Kolberg Hans-Christian, Hadji Peyman, Tesch Hans, Häberle Lothar, Ettl Johannes, Lux Michael P, Luftner Diana, Wallwiener Markus, Schneeweiss Andreas
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
Widschwendter P, Jueckstock J, Neugebauer J, Trapp E, Fasching P, Beckmann M, Schneeweiss A, Schrader I, Rack B, Janni W, Andergassen U, Kost B, Friedl T, Schwentner L, DeGregorio N, Jaeger B, Schramm A, Bekes I, Deniz M, Lato K, Weissenbacher T, Scholz C. The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. Breast Cancer Res 2015; 17:129.
18.09.2015The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
18.09.2015Breast Cancer Res 2015; 17:129
Widschwendter Peter, Jueckstock Julia, Neugebauer Julia, Trapp Elisabeth, Fasching Peter A, Beckmann Matthias W, Schneeweiss Andreas, Schrader Ines, Rack Brigitte, Janni Wolfgang, Andergassen Ulrich, Kost Bernd, Friedl Thomas Wp, Schwentner Lukas, DeGregorio Nikolaus, Jaeger Bernadette, Schramm Amelie, Bekes Inga, Deniz Miriam, Lato Krisztian, Weissenbacher Tobias, Scholz Christoph
Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
Hein A, Ekici A, Hanusch C, Huober J, Liedtke C, Mau C, Moisse M, Müller V, Nekljudova V, Peuteman G, Rack B, Rübner M, Van Brussel T, Wang L, Weinshilboum R, Loibl S, Beckmann M, Kunz G, Lambrechts D, von Minckwitz G, Häberle L, Eidtmann H, Tesch H, Untch M, Hilfrich J, Schem C, Rezai M, Gerber B, Dan Costa S, Blohmer J, Schwedler K, Kittel K, Fehm T, Fasching P. Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study. Int J Cancer 2015; 137:2981-8.
06.07.2015Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
06.07.2015Int J Cancer 2015; 137:2981-8
Hein Alexander, Ekici Arif B, Hanusch Claus, Huober Jens, Liedtke Cornelia, Mau Christine, Moisse Matthieu, Müller Volkmar, Nekljudova Valentina, Peuteman Gilian, Rack Brigitte, Rübner Matthias, Van Brussel Thomas, Wang Liewei, Weinshilboum Richard M, Loibl Sibylle, Beckmann Matthias W, Kunz Georg, Lambrechts Diether, von Minckwitz Gunter, Häberle Lothar, Eidtmann Holger, Tesch Hans, Untch Michael, Hilfrich Jörn, Schem Christian, Rezai Mahdi, Gerber Bernd, Dan Costa Serban, Blohmer Jens-Uwe, Schwedler Kathrin, Kittel Kornelia, Fehm Tanja, Fasching Peter A
14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts
Jackisch C, Blohmer J, Costa S, Decker T, Diel I, Fasching P, Fehm T, Janni W, Lück H, Maass N, Scharl A, Beckmann M, Loibl S, Thomssen C, Harbeck N, Huober J, von Minckwitz G, Gerber B, Kreipe H, Liedtke C, Marschner N, Möbus V, Scheithauer H, Schneeweiss A, Untch M. 14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts. Breast Care (Basel) 2015; 10:211-9.
23.06.201514th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts
23.06.2015Breast Care (Basel) 2015; 10:211-9
Jackisch Christian, Blohmer Jens-Uwe, Costa Serban-Dan, Decker Thomas, Diel Ingo, Fasching Peter A, Fehm Tanja, Janni Wolfgang, Lück Hans-Joachim, Maass Nicolai, Scharl Anton, Beckmann Matthias W, Loibl Sibylle, Thomssen Christoph, Harbeck Nadia, Huober Jens, von Minckwitz Gunter, Gerber Bernd, Kreipe Hans-Heinrich, Liedtke Cornelia, Marschner Norbert, Möbus Volker, Scheithauer Heike, Schneeweiss Andreas, Untch Michael
Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies
Salmen J, Sohn C, Fehm T, Mohrmann S, Loehberg C, Hein A, Schulz-Wendtland R, Hartkopf A, Brucker S, Wallwiener D, Friese K, Hartmann A, Beckmann M, Janni W, Rom J, Heil J, Neugebauer J, Fasching P, Haeberle L, Huober J, Wöckel A, Rauh C, Schuetz F, Weissenbacher T, Kost B, Stickeler E, Klar M, Orlowska-Volk M, Windfuhr-Blum M, Rack B. Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. Breast Cancer Res Treat 2014; 148:143-51.
25.09.2014Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies
25.09.2014Breast Cancer Res Treat 2014; 148:143-51
Salmen Jessica, Sohn Christof, Fehm Tanja, Mohrmann Svjetlana, Loehberg Christian R, Hein Alexander, Schulz-Wendtland Ruediger, Hartkopf Andreas D, Brucker Sara Y, Wallwiener Diethelm, Friese Klaus, Hartmann Arndt, Beckmann Matthias W, Janni Wolfgang, Rom Joachim, Heil Joerg, Neugebauer Julia, Fasching Peter A, Haeberle Lothar, Huober Jens, Wöckel Achim, Rauh Claudia, Schuetz Florian, Weissenbacher Tobias, Kost Bernd, Stickeler Elmar, Klar Maximilian, Orlowska-Volk Marzenna, Windfuhr-Blum Marisa, Rack Brigitte
Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer
Mouridsen H, Thürlimann B, Robidoux A, Llombart-Cussac A, Gligorov J, Doughty J, Blackwell K, Beckmann M, Lønning P, Gnant M. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Rev Anticancer Ther 2010; 10:1825-1836.
30.09.2010Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer
30.09.2010Expert Rev Anticancer Ther 2010; 10:1825-1836
Mouridsen Henning T, Thürlimann Beat, Robidoux Andre, Llombart-Cussac Antonio, Gligorov Joseph, Doughty Julie, Blackwell Kimberly, Beckmann Matthias W, Lønning Per, Gnant Michael